Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 1432 Pancreatic Neoplasms 860 Carcinoma, Hepatocellular 743 Stomach Neoplasms 647 Colonic Neoplasms 447 Rectal Neoplasms 404 Esophageal Neoplasms 398 Breast Neoplasms 331 Carcinoma, Non-Small-Cell Lung 326 Neoplasms 307 Liver Neoplasms 282 Cholangiocarcinoma 244 Ovarian Neoplasms 243 Lung Neoplasms 237 Neoplasm Metastasis 235 Gastrointestinal Neoplasms 217 Melanoma 185 Prostatic Neoplasms 166 Esophageal Squamous Cell Carcinoma 166 Biliary Tract Neoplasms 161 Endometrial Neoplasms 143 Uterine Cervical Neoplasms 130 Squamous Cell Carcinoma of Head and Neck 129 Carcinoma, Renal Cell 114 Head and Neck Neoplasms 113 Sarcoma 100 Urinary Bladder Neoplasms 97 Adenocarcinoma Of Esophagus 90 Triple Negative Breast Neoplasms 86 Anus Neoplasms 83

Interventions

trifluridine tipiracil drug combination 1 reolysin 1 atezolizumab 1 Gemcitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Anal Cancer Metastatic × Gastrointestinal × 1 year × Clear all

NCT07280377 2026-05-19

GOBLET

Oncolytics Biotech

Phase 1/2 Active not recruiting

Gastrointestinal

Anal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡